Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/dth.15470 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Treatment Persistence Among Anti-Tumor Necrosis Factor-experienced Patients With Ulcerative Colitis Switching to a Biologic With a Different Mode of Action or Cycling to Another Anti-Tumor Necrosis Factor Agent.
Clin Ther
December 2024
Analysis Group, Inc, Montreal, Quebec, Canada.
Purpose: In ulcerative colitis (UC), anti-tumor necrosis factor (TNF) agents often are first-line biologic therapy. Switching to a biologic with a different mode of action (ustekinumab and vedolizumab) or cycling to another anti-TNF agent (adalimumab, infliximab, and golimumab) is necessary if an initial anti-TNF fails. This study compared real-world persistence in patients with UC who switched to a biologic with a different mode of action or cycled with another anti-TNF after nonresponse to an anti-TNF.
View Article and Find Full Text PDFBiosimilar SB17 versus reference ustekinumab in moderate to severe plaque psoriasis after switching: phase 3 study results up to week 52.
J Dermatolog Treat
December 2024
Samsung Bioepis, Co. Ltd, Incheon, South Korea.
Introduction: SB17 is a biosimilar to reference ustekinumab (UST). We compared the efficacy, safety, and immunogenicity of SB17 to UST up to Week 52, including switching from UST to SB17.
Methods: Subjects were randomized to receive 45 mg of SB17 or UST subcutaneously up to Week 40.
Post-Marketing Safety of Ustekinumab Based on 14-Year Follow-Up in Danish National Patient Data.
Pharmacoepidemiol Drug Saf
December 2024
Department of Pediatrics and Adolescent Medicine, Danish National University Hospital "Rigshospitalet", Copenhagen, Denmark.
Article Synopsis
- This 14-year cohort study investigated the long-term safety of ustekinumab, a biologic treatment for psoriasis, using data from Danish national registers.
- The study compared safety outcomes like cancers and serious infections in ustekinumab users against patients receiving other systemic treatments, including non-biologics and various biologic therapies.
- Results showed that ustekinumab is generally safe, with no major safety concerns identified, and users were younger and had different gender distributions compared to users of other treatments.
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.
Lancet
December 2024
Dr Henry D Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Background: Mirikizumab, a humanised monoclonal antibody that inhibits IL-23p19, is effective in moderate-to-severe ulcerative colitis. We aimed to evaluate the efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease.
Methods: VIVID-1 was a global phase 3, randomised, double-blind, double-dummy, placebo-controlled and active-controlled, treat-through study.
Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study.
Dermatol Ther (Heidelb)
December 2024
Institute and Comprehensive Center Inflammation Medicine, University of Lübeck, Lübeck, Germany.
Introduction: Risankizumab has demonstrated superior efficacy compared to other psoriasis treatments, including secukinumab, adalimumab, and ustekinumab; switching to risankizumab from other psoriasis treatments has shown superior clinical and quality of life (QoL) outcomes. We evaluated the efficacy and safety of directly switching patients with moderate-to-severe plaque psoriasis and a suboptimal response to interleukin (IL)-17 inhibitors (secukinumab or ixekizumab) to risankizumab.
Methods: This 52-week, phase 3b study enrolled patients (≥ 18 years) with moderate-to-severe plaque psoriasis who had previously been treated with the recommended dose of secukinumab or ixekizumab for ≥ 6 months but did not achieve an optimal response (static Physician's Global Assessment [sPGA] 2/3; body surface are [BSA] 3- < 10%).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!